NIT
KPTI icon

NumerixS Investment Technologies’s Karyopharm Therapeutics KPTI Stock Holding History

NumerixS Investment Technologies’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-364
Closed -$103K – 449
2020
Q2 		$103K Buy
+364
New +$108K 0.03% 580
2019
Q1 		– Sell
-147
Closed -$20K – 1232
2018
Q4 		$20K Buy
+147
New +$24.8K 0.01% 923

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NumerixS Investment Technologies's KPTI Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 364 shares — an estimated $103K sold.

NumerixS Investment Technologies first reported a position in KPTI in Q4 2018 and held it in 2 quarters. The position peaked at $103K in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • NumerixS Investment Technologies reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 364 Karyopharm Therapeutics shares in Q3 2020, an estimated $103K.
  • NumerixS Investment Technologies first reported a position in Karyopharm Therapeutics in Q4 2018 and held it in 2 quarters.
  • NumerixS Investment Technologies's Karyopharm Therapeutics position peaked at $103K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.